Atossa Therapeutics, Inc.
ATOS · NASDAQ
Bulios Fair Price
$2.26
7.4% downside
Current Price
$2.44
According to Bulios Fair Price, ATOS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Atossa Therapeutics, Inc. (ATOS) is a biotechnology company focused on the development and commercialization of drugs and therapies in the fields of oncology and women's health. The company concentrates on researching new medications and diagnostic methods aimed at the prevention and treatment of various types of cancer, including breast cancer. Atossa Therapeutics also develops innovative treatments and therapeutic approaches to enhance women's health. Shares of Atossa Therapeutics, Inc. (ATOS) can be an interesting choice for investors tracking the biotechnology sector and the development of drugs and therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Steven C. Quay
Employees
16
Headquarters
Seattle
Upcoming events
Earnings
Upcoming earnings report